Phase 3 VITESSE data highlight clinical impact of VIASKIN peanut patch

In a recent discussion with Contemporary Pediatrics, David Fleischer, MD, professor of pediatrics at Children’s Hospital Colorado, reviewed the phase 3 VITESSE trial data evaluating the VIASKIN peanut patch, an epicutaneous immunotherapy designed to desensitize children with peanut allergy.

He emphasized that the responder rate after 12 months is clinically meaningful and supports real-world application. Nearly 80% of children treated with the patch increased their eliciting dose by at least 1 dose level, compared with approximately 48% in the placebo group.

Notably, approximately 60% of treated patients increased their eliciting dose by 2 or more dose levels. Because the primary goal of therapy is to raise the threshold at which a child reacts to peanut exposure, this increase offers meaningful protection against accidental ingestion, either preventing reactions altogether or reducing their severity.

Fleischer clarified that the responder definition required children to tolerate a prespecified peanut dose at 12 months, determined in part by their baseline reactivity. For many participants who initially reacted to very small amounts (often less than 30 to 100 mg of peanut protein), achieving tolerance equivalent to 1 to 2 peanuts represents a substantial improvement in protection.

Consistent with other immunotherapy studies, younger children tend to experience greater benefit. Although VITESSE enrolled children aged 4 to 7 years, prior data in children aged 1 to 3 years demonstrated even stronger treatment effects, reinforcing the importance of early intervention.

From a safety perspective, the patch demonstrated a favorable profile. Rates of anaphylaxis were low, in the range of 1% to 2%. Local skin reactions were common, as expected with epicutaneous allergen delivery, but most were manageable and did not lead to discontinuation.

Overall dropout rates were low and adherence was high, reflecting the therapy’s ease of use. Unlike oral immunotherapy, the patch does not require in-office dose escalations or activity restrictions during illness or exercise, enhancing practicality for families.

Subgroup analyses revealed consistent efficacy and safety across different patient populations, with no significant differences observed. Looking ahead, long-term open-label extension studies will assess durability of response and sustained unresponsiveness after discontinuation.

A biologics license application submission is planned for the first half of 2026, and if approved, the therapy may offer a safe, convenient desensitization option. Fleischer encouraged pediatricians to refer eligible patients early, as earlier initiation appears to yield greater benefit.

No relevant disclosures.

Reference:

Ebert M. Phase 3 trial meets primary endpoint for Viaskin peanut patch in children aged 4 to 7 years. Contemporary Pediatrics. December 17, 2025. Accessed February 27, 2026. https://www.contemporarypediatrics.com/view/phase-3-trial-meets-primary-endpoint-for-viaskin-peanut-patch-in-children-aged-4-7-years